The new production line is equipped with the latest advanced manufacturing system to produce quality products of Alkaloids & APIs used in a wide range of pharmaceutical applications
The company sees the business reaching $100mn
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
Subscribe To Our Newsletter & Stay Updated
